| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443265 | European Journal of Cancer | 2014 | 11 Pages |
Abstract
We demonstrated that intravenous injections of CD-MSC cells, followed by intraperitoneal administration of 5-fluorocytosine, caused tumour regression in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model, which develops aggressive and spontaneous prostate cancer. These results add new insights to the therapeutic potential of specifically engineered MSC in prostate cancer disease.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Alberto Abrate, Roberta Buono, Tamara Canu, Antonio Esposito, Alessandro Del Maschio, Roberta Lucianò, Arianna Bettiga, Giorgia Colciago, Giorgio Guazzoni, Fabio Benigni, Petter Hedlund, Cestmir Altaner, Francesco Montorsi, Ilaria T.R. Cavarretta,